Dr. Jennifer Nuzzo, lead epidemiologist for Hopkins' coronavirus resource center’s Testing Insights Initiative, on the challenges and confusion COVID-19 reporting inconsistencies create and what the next steps could be. 

Johns Hopkins Bloomberg School of Public Health Professor and Virologist Andrew Pekosz on realistic expectations for a coronavirus vaccine.

Infusing hospitalized COVID-19 patients with blood plasma from people who recovered from the disease had no effect on whether patients got sicker or died, according to the first completed randomized trial of the treatments.

The new guidance is likely to have the biggest impact on schools, workplaces and other group settings since more people are likely to be considered at risk.

Dr. Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, on why he believes COVID-19 will continue infect new patients every year, similar to the influenza.

After weeks of warnings that cases were again on the rise, a third surge of coronavirus infection has firmly taken hold in the United States.

Blood from the most severely ill COVID-19 patients may be the best for use in convalescent plasma therapy, according to a new study from Johns Hopkins University.

On Thursday, the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, meets for the first time to consider COVID-19 vaccines.

Hopkins expert Jennifer Nuzzo on why the US response to COVID-19 continues along on the wrong path.

Hopkins experts Kyra Grantz and Justin Lessler on overdispersion in the COVID-19 pandemic.

Soon COVID-19 vaccine makers will release early data from large clinical trials, and the results could be ambiguous.

Johns Hopkins Bloomberg School of Public Health Vice Dean Joshua Sharfstein warns that Covid-19 deaths in the U.S. could triple without the right containment strategy.